Sensitivity analyses for the principal ignorability assumption using multiple imputation
License
Access Rights
Cadmus Permanent Link
Full-text via DOI
ISBN
ISSN
1539-1604; 1539-1612
Issue Date
Type of Publication
Keyword(s)
LC Subject Heading
Other Topic(s)
EUI Research Cluster(s)
Initial version
Published version
Succeeding version
Preceding version
Published version part
Earlier different version
Initial format
Citation
Pharmaceutical statistics, 2023, Vol. 22, No. 1, pp. 64-78
Cite
WANG, Craig, ZHANG, Yufen, MEALLI, Fabrizia, BORNKAMP, Björn, Sensitivity analyses for the principal ignorability assumption using multiple imputation, Pharmaceutical statistics, 2023, Vol. 22, No. 1, pp. 64-78 - https://hdl.handle.net/1814/77839
Abstract
In the context of clinical trials, there is interest in the treatment effect for subpopulations of patients defined by intercurrent events, namely disease-related events occurring after treatment initiation that affect either the interpretation or the existence of endpoints. With the principal stratum strategy, the ICH E9(R1) guideline introduces a formal framework in drug development for defining treatment effects in such subpopulations. Statistical estimation of the treatment effect can be performed based on the principal ignorability assumption using multiple imputation approaches. Principal ignorability is a conditional independence assumption that cannot be directly verified; therefore, it is crucial to evaluate the robustness of results to deviations from this assumption. As a sensitivity analysis, we propose a joint model that multiply imputes the principal stratum membership and the outcome variable while allowing different levels of violation of the principal ignorability assumption. We illustrate with a simulation study that the joint imputation model-based approaches are superior to naive subpopulation analyses. Motivated by an oncology clinical trial, we implement the sensitivity analysis on a time-to-event outcome to assess the treatment effect in the subpopulation of patients who discontinued due to adverse events using a synthetic dataset. Finally, we explore the potential usage and provide interpretation of such analyses in clinical settings, as well as possible extension of such models in more general cases.
Table of Contents
Additional Information
Published online: 23 August 2022